What DynamiCure does

DynamiCure is a privately held, pre-revenue biopharmaceutical company founded in July 2019 by Dr. Lieping Chen of Yale University and headquartered in Waltham, Massachusetts. The company is developing a pipeline of therapeutic monoclonal antibody candidates based on an immuno-normalization platform, with its core focus on the DC-6001 anti-CD93 program. DynamiCure's scientific thesis centers on blocking CD93, a receptor downstream of VEGF-A, to normalize abnormal tumor vasculature rather than simply inhibiting angiogenesis. This approach aims to reduce tumor hypoxia and convert immunosuppressive tumor microenvironments into immunostimulatory ones, with the goal of enhancing the efficacy of existing immunotherapies and chemotherapeutic agents.

The company's lead candidate, DCBY02, is a monoclonal antibody targeting a specific CD93 epitope that demonstrated distinct in vitro and in vivo properties and anti-tumor activity in preclinical studies. The FDA cleared an IND for DCBY02 in August 2022, and the company dosed first patients in a multicenter, open-label Phase 1 trial in November 2022 evaluating the candidate across multiple advanced or metastatic solid tumor indications, including colorectal, gastric, non-small cell lung, renal cell, breast, hepatocellular, ovarian, cervical, head and neck cancers, and glioblastoma multiforme. A second anti-CD93 antibody, DCSZ11, targets a different CD93 epitope and is advancing toward IND submission expected in Q4 2022. DynamiCure also has an autoimmune disease program built around an undisclosed target licensed from Dr. Chen's research, extending the immuno-normalization concept beyond oncology.

The business model is a traditional clinical-stage biopharmaceutical structure. The company has worldwide exclusive commercial licenses from Yale University and the University of Colorado Anschutz Medical Campus for CD93 and other novel targets, obtained through co-development partnerships with scientific founders Drs. Lieping Chen and Yuwen Zhu. DynamiCure operates full in-house R&D and integrated CMC capabilities from a 17,000 square foot laboratory facility in Waltham, with plans to commercialize products through traditional pharmaceutical channels or licensing partnerships upon regulatory approval. As a pre-revenue company with 11–50 employees, DynamiCure's go-to-market is clinical trial execution at academic cancer centers across North America, supported by scientific publications, press releases, and engagement with the medical community.

Name

DynamiCure

Legal name

DynamiCure Biotechnology, LLC

Website

https://dynamicure.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

DynamiCure is a pre-revenue biopharmaceutical company developing monoclonal antibody candidates that target the CD93 pathway to normalize tumor vasculature in cancer and treat autoimmune diseases. Founded in 2019 and headquartered in Waltham, Massachusetts, with lead candidate DCBY02 in Phase 1 clinical trials.

Ownership category

akta.pro rank

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue biopharmaceutical company expecting to generate revenue through commercialization of therapeutic antibody products upon regulatory approval. Revenue would come from sales of proprietary antibody drugs for treatment of cancer and autoimmune diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

DynamiCure is a clinical-stage biopharmaceutical company developing a pipeline of monoclonal antibody therapeutic candidates targeting the CD93 pathway to normalize tumor vasculature and convert immunosuppressive tumor microenvironments into immunostimulatory ones. The company's lead asset DCBY02 is in Phase 1 clinical trials for advanced solid tumors, while a second candidate DCSZ11 is advancing toward IND submission. The pipeline also includes an undisclosed autoimmune disease program, with the company leveraging exclusive worldwide licenses from Yale University and University of Colorado.

Product overview

DynamiCure is a biopharmaceutical company developing a pipeline of innovative therapeutic antibody candidates with first-in-class and best-in-class potential. The company's core focus is the DC-6001 anti-CD93 program, which consists of two monoclonal antibodies—DCBY02 and DCSZ11—each targeting different epitopes of the CD93 receptor. DCBY02 is currently in Phase 1 clinical trials for advanced solid tumors, while DCSZ11 is advancing toward IND submission. The company employs a platform-agnostic approach to translate immuno-normalization insights into therapeutics for oncology and autoimmune disease, with full in-house drug discovery and development capabilities including CMC capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• DCBY02 Lead anti-CD93 monoclonal antibody candidate that normalizes malignant tumor vasculature and converts the tumor microenvironment from immunosuppressive to immunostimulatory. Currently in Phase 1 clinical development for advanced/metastatic solid tumors including colorectal, gastric, non-small cell lung, renal cell, breast, hepatocellular, ovarian, cervical, head and neck cancers, and glioblastoma multiforme.
• DCSZ11 Second monoclonal antibody candidate from the DC-6001 program targeting a different epitope of the CD93 receptor than DCBY02. Demonstrated distinct in vitro and in vivo properties and anti-tumor activity in pre-clinical development. IND submission expected Q4 2022.
• DC-6001 Anti-CD93 Program DynamiCure's anti-CD93 development program consisting of two monoclonal antibodies (DCBY02 and DCSZ11), each blocking different epitopes of the CD93 receptor. Designed to enhance efficacy of immunotherapies and chemotherapeutic agents by normalizing tumor vasculature.

Quantifiable outcome

• Phase 1 trial evaluating DCBY02 in up to 36 participants (Part 1 dose-escalation) and up to 60 participants (Part 2 dose-expansion)
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• University of Colorado Anschutz Medical CampuscoreStrategic or Co-development Partner · 1 October 2019DynamiCure obtained exclusive worldwide commercial licenses from University of Colorado for CD93 and other novel targets from Dr. Yuwen Zhu's research. Dr. Zhu, Associate Professor of Surgical Oncology, focuses on normalizing tumor vasculature to improve drug and immune system access to tumors. Ongoing collaboration continues for additional research programs.
• Yale UniversitycoreStrategic or Co-development Partner · 1 July 2019DynamiCure was founded by Dr. Lieping Chen from Yale University. The company has obtained exclusive worldwide commercial licenses from Yale for several novel targets resulting from Dr. Chen's research, including CD93. The company continues to collaborate with Yale laboratories on additional research programs.
• Dr. Lieping ChencoreStrategic or Co-development PartnerScientific co-founder of DynamiCure, Dr. Chen is a world-renowned immunologist and oncologist at Yale University. His pioneering work uncovered the immunosuppressive role of the PD-1/PD-L1 pathway. He is United Technologies Corporation Professor in Cancer Research at Yale and co-leader of the Cancer Immunology Program at Yale Cancer Center. Elected to Academia Sinica of Taiwan and US National Academy of Sciences.
• Dr. Yuwen ZhucoreStrategic or Co-development PartnerResearch collaborator whose work focuses on normalizing tumor vasculature to improve pathways to tumors. Associate Professor of Surgical Oncology at University of Colorado Anschutz Medical Campus, with prior cancer immunotherapy research at Johns Hopkins Medical and Yale University.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dynamicure

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DynamiCure